A novel assay system has been developed in which expression of a human tissue-plasminogen activator (t-PA) gene, carried on a recombinant papillomavirus vector, is used as a marker for the presence of bovine papillomavirus type 1 (BPV-1) within transformed mouse C127 cells. This provides a relatively quick and simple means of identifying and evaluating agents with anti-papillomavirus activity. Using this system the antiviral activity and cytotoxicity of interferon and retinoic acid, have been investigated. After seven subcultures in the presence of 200 Units ml-1 mouse ex and f3 interferon, t-PA expression was completely inhibited, with a concurrent alteration in cellular morphology, and restoration of contact inhibition. In accordance with the problems encountered with interferon therapy of human papillomavirus infections, these effects were dependent on the continued presence of interferon, its removal leading to a rapid return of t-PA expression, and reversion of cells to the transformed phenotype. In comparison, 2.0/.1g ml " retinoic acid partially reduced t-PA expression (this effect was largely maintained even after removal of the inhibiting compound) but did not affect the transformed cell phenotype. These results are discussed in relation to other in vitro studies and also to the clinical treatment of human papillomavirus (HPV) disease.
Introduction
Papillomaviruses induce benign tumours of the skin and mucous membranes in man and animals (Singer and Campion, 1985) . Certain types of human papillomavirus (HPV) are associated with benign lesions of the human genital tract (HPV-6, -11), others such as HPV-16 and -18 Resubmitted 12 July, 1991; accepted 17 July, 1991. *For correspondence. Tel. 0737-364400; Fax 0737-364440. occur consistently in advanced intra-epithelial neoplasia and cervical carcinomas (Fuchs et a/., 1988; Zur Hausen, 1987; Zur Hausen and Schneider, 1987) .
The strong association of papillomaviruses with the development of genital tract neoplasias, and the rapidly increasing incidence of this sexually transmitted disease (Becker et al., 1987; Kjaer and Lynge, 1989 ) have led to an increased interest in the appropriate management of these infections. Completely safe and effective modes of therapy are not available, most current therapies relying on surgical excision, cytotoxic or destructive treatments (Reichman and Strike, 1989; Eskelinen and Mashkilleyson, 1987) . Positive therapeutic effects have been shown with interferon (Reichman et a/., 1988; Schneider et aI., 1987) , and evidence also points to the efficacy of retinoids in inducing regression of several HPV-associated lesions (Lutzner et el., 1984; Gross et aI., 1983; Hong et a/., 1986) . However, therapy is limited by the efficacy of the treatments, the high degree of recurrence and the toxic reactions observed. The discovery of an effective and selective antiviral chemotherapeutic agent is required for the successful treatment of papillomavirus infections. The development of model systems for the study of HPVs, their role in human neoplasia and their chemotherapy, has been hampered by the lack of a permissive tissue culture system for viral propagation. However, an in vitro system for studying papillomavirus genetics is provided by the ability of the bovine papillomavirus type 1 (BPV-1) genome to persist in and transform rodent cells (Nakabayashi et a/., 1984) . Although some integration of viral DNA can occur in the host chromosomal material, the BPV genome generally replicates in the transformed cells as an episomal element. It is this system that has enabled much of the present information on the mechanism of papillomavirus-induced transformation to be gained.
We had originally developed a number of BPV-1 transformed C127 cell lines, in which a human tissue-type plasminogen activator (t-PA) gene was incorporated into a BPV-1 vector, as part of a programme to synthesize recombinant t-PA (Browne et al., 1988) . It occurred to us that such cell lines could form the basis of a rapid assay system in which the t-PA gene could act as a marker for the presence and expression of the viral genome. Here we describe thl!l development of a novel assay system which provides the first simple means of detecting agents with Assay Plate Fig. 1 . t-PA based marker gene assay for detecting agents with anti-papillomavirus activity. Compound cytotoxicity is recorded as the minimum concentration (JLg rnr ') causing a decrease in the staining of the cell monolayer on the assay plate, or macroscopic change compared with controls. Antiviral activity is expressed as the concentration (JLg rnr') of compound inhibiting the t-PA (and hence SPV) induced fibrinolysis zone size by 50% compared with controls. Samples A, S, C, D, and Fare non-toxic and inactive, E, G, and H appear active, but this is, in fact, a result of their cytotoxicity. ....
anti-papillomavirus activity. We illustrate its clinical relevance by evaluating the response of the system to two agents used in the treatment of HPV disease, namely, interferon and retinoic acid.
Results

Anti-papil/omavirus assay
The t-PA gene marker assay that we describe here provides a quick and simple primary screening system for detecting agents with anti-papillomavirus activity ( Fig. 1 ). Treatment of BPV-1 transformed C127 cells (310) with test compounds, followed by bioassay for t-PA in the culture medium, produces lysis zones in a fibrin gel which are proportional in size to the concentration of t-PA present (Dodd et aI., 1985) .This provides a means of assessingthe levels of t-PA gene expression, and hence the presence of the BPV genome, in the compound treated cells. Antiviral activity is determined in conjunction with an evaluation of compound cytotoxicity. This is important, as frank cytotoxicity will also result in otherwise misleading decreased levels of t-PA. The screening strategy assumes that agents displaying apparent selective anti-papillomavirus activity will be further tested for direct effects on t-PA, and for effects on viral DNA content by hybridization studies.
Evaluation of the anti-papil/omavirus activity of interferon and retinoic acid
The anti-papillomavirus activity of these agents was determined by culturing the C127 and 310 cells in the presence or absence of 200 U mr' mouse interferon or 2.0 fL9 ml" retinoic acid. During the course of the study, selective antiviral action was determined by analysis of compound cytotoxicity, effects on the transformed cell phenotype, and by the t-PA marker gene assay. Antiviral determinations made by the t-PA system, reveal a difference between the action of interferon and retinoic acid (Fig. 2 ). Treatment of 310 cells with 200 U mr' mouse interferon produced a rapid, complete inhibition of fibrinolysis. However, on removal of interferon from the culture, t-PA expression rapidly returned to a level comparable to the untreated 310 cells.
In contrast, treatment with retinoic acid produced a persistent, but incomplete, effect on 310 cells, with levels of 2.0 fLg mr' reducing t-PA expression by approximately 90%. This effect was largely maintained even after removal of the retinoic acid, the level of suppression then being 77% of untreated control levels.
To establish that the observed reduction in t-PA expression by interferon and retinoic acid was the result of antiviral effects and not t-PA inhibition, both agents were tested for their ability to inhibit t-PA. directly. Neither interferon nor retinoic acid, when diluted to their experimental concentrations in a solution of t-PA produced any significant inhibition of t-PA activity. These agents, therefore, do not act as t-PA inhibitors. (Results not shown.)
In the t-PA marker gene system, reduction in fibrinolysis may be the result of either removal of BPV DNA from the transformed cells, for example by inhibition of viral episomal replication, or by inhibition of gene expression. The levels of viral DNA in the treated and untreated 310 cells were therefore investigated using a BPV-specific DNA probe.
Dot blots of 310 cells taken after 10 weeks continual passage in the presence of either 200 U rnr' mouse interferon or 2.0 f.Lg mr' retinoic acid, revealed no significant difference in the levels of BPV-1 DNA compared to the untreated 310 cells (Fig. 3 ). Interferon and retinoic acid therefore appear to have no effect on the viral DNA content of the BPV-1-transformed C127 cells, and the precise mechanism of inhibition of t-PA expression thus remains to be elucidated. Analysis of cellular growth characteristics revealed 200U mr' mouse interferon was able to reduce specifically the high saturation densities of the transformed cells to a level nearer that of the untransformed C127 cells ( Fig.  4a and b ). Interferon treatment produced minimal effects on C127 cell growth, indicating that the observed reduction in 310 cell numbers was the apparent result of a restoration of contact inhibition and not the result of non-specific compound cytotoxicity. As with the effects on t-PA expression, this reduction was dependent on the continued presence of interferon; its removal leading to a rapid return to control levels.
Continuous passage in the presence of 2.0 f.Lg rnr'
retinoic acid decreased 310 cell saturation densities by approximately 50% (Fig.4c and d) , but as the same extent of cellular growth repression occurred with the C127 cells, this can be attributed to non-specific cytotoxic effects. On removal of compound, cell numbers returned to control levels. Thus, in contrast to the action of interferon, the effect of retinoic acid on 310 cell growth was not specific. In agreement with the effects observed on transformed cell growth, morphological examination of interferontreated 310 cells showed a rapid reversion to a more Passage number of cells Passage number of cells ordered cell appearance with acquisition of contact inhibition, a characteristic of the untransformed cells (Fig. 5 ). This morphological reversion was dependent on the continued presence of interferon, its withdrawal resulting in a rapid return to cellular overgrowth which is a characteristic of the transformed cell. No such morphological changes resulted after treatment with retinoic acid.
Discussion
The aim of a primary screening system is to provide a relatively quick and simple means of testing many samples in order to identify a few agents of interest that can then be evaluated in greater depth. The marker gene based anti-papillomavirus assay, described here, fulfils such criteria. The use of t-PA as a marker gene provides a highly sensitive detection system for the presence of the viral genome. Fibrinolysis occurs via the conversion, by t-PA, of the inactive proenzyme plasminogen to the active enzyme plasmin, which then degrades insoluble fibrin (Collen et al., 1989; Verstraete and Collen, 1986) . It is this intermediary stage of plasminogen activation that allows the effects of very small amounts of t-PA to be amplified, to give measurable zones of fibrinolysis proportional in size to the concentration oft-PA. As a result, effects on the t-PA expression cassette, caused either by inhibition of viral DNA replication or general suppression of gene expression, can readily be ascertained. The system could also easily be adapted to a microtitre format to allow greater screening capacity.
In an area where screening for antiviral agents is hampered by the lack of a permissive tissue culture system for papillomaviruses, this assay system provides a sensitive and simple means of assessing compound effects on papillomavirus DNAs within transformed cells. In comparison with alternative radio-labelled probing techniques it is much simpler and quicker to perform, allows greater sample throughput, uses stable reagents, and avoids exposure to radioisotopes with their attendant problems (Matthews, et al., 1985) .
Although BPV transformation models display some differences to HPV models, this has to be seen in the perspective that there are currently no simple antiviral screens available in this area.The novel system described here is the first rapid means of detecting chemotherapeutic agents with activity against papillomaviruses.
A major issue confronting this assay system is its relevance to the clinical situation. To address this we chose to follow the effect of agents already tested against papillomavirus infection in the clinic, on 310 cells. For the purposes of this study (i.e. screen validation), a limited exposure time, was selected. This allowed observations to 
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be made during and after drug treatment, that closely mirror those found clinically.
In the antiviral evaluation of interferon, treatment of 310 cells with 200 U mr" mouse interferon did not appear to affect the levels of BPV DNA within the transformed cells, but a rapid, complete inhibition of t-PA expression was induced. Without evidence of direct t-PA inactivation, or reduction in viral DNA levels, it would appear that interferon is acting by suppression of gene expression. In addition, observation of phenotypic parameters indicates a concurrent reduction in the transformed cell high saturation densities to a level nearer that of the untransformed C127 cells with morphological reversion to more untransformed cell characteristics. In all cases, these effects were dependent on the continued presence of interferon; its removal leading to a rapid return to control levels.
Examination of the effect of mouse L-cell interferon on BPV-1 transformation of C127 cells by Turek et al. (1982) revealed a similar induction of morphologic reversion, but with elimination of extrachromosomal viral genomes. As will be discussed, the presence of integrated BPV DNA in the cell system used in our studies could prevent such elimination.
Our data do appear to indicate a mechanism of temporary suppression of gene expression, rather than elimination of viral DNA. The former has also been suggested by Nawa et al. (1990) . In their studies, selective inhibition of HPV 18 gene expression in HeLa cells by interferon ex and 'Y was shown to occur at the level of transcription. Furthermore, our in vitro observations also appear to correlate with many clinical investigations. Several studies have shown the use of either topical or systemic interferon, for the treatment of laryngeal and genital human papillomavirus infections, produce a positive therapeutic effect. This is, however, followed by frequent recurrence of disease after cessation of interferon treatment (Friedman-Kien et aI., 1988; and Rando, 1988) .
Interestingly, the effects of retinoic acid on BPV-1transformed C127 cells show several differences to those observed with interferon. Treatment of 310 cells with 2.0 JLg mr' retinoic acid did not appear to reduce viral DNA levels and (despite clear evidence of non-specific growth inhibition) cellular growth characteristics were not altered in a manner indicative of reversion to the untransformed phenotype. However, lasting and specific inhi- retinoic acid, was revealed by the t-PA based system. The additional 15% reduction observed prior to the withdrawal of retinoic acid from culture, resulting in apparent inhibition levels of 92%, probably reflect direct cytotoxic effects, as evidenced by the concurrent reduction in cell saturation densities. These in vitro data show significant, but not complete, repression of gene expression after cessation of treatment with retinoic acid. Analysis of the state of the viral DNA within the 310 cells used in these evaluations showed evidence of some viral integration (data not shown), and clearly the ability of a compound, to completely inhibit expression or remove viral DNA, becomes much more difficult once the DNA becomes integrated into the host chromosomal material. Relating this to clinical observations, it could be speculated that some of the lesions redevelop from cells that continue to harbour actively expressed papillomavirus genes.
Although Li et at. (1988) showed that retinoic acid treatment of BPV-1-transformed C127 cells (in which the viral DNA was episomal) results in 'curing' of the viral DNA, they studied isolated sub-clones rather than whole cell populations. We feel that the results we have obtained using a whole population of treated cells (which may not be homogeneous with respect to the number of BPV DNA copies per cell, perhaps due to genetic instability), are probably more relevant to the clinical situation where retinoid treatment leads to lesion suppression, but not eradication.
Retinoid compounds have been administered to various HPV-associated human lesions; oral leukoplakia (Hong et a/., 1986) , Bowen's disease, common warts (Gross et a/., 1983) , and epidermodysplasia verruciformis (Lutzner et sl., 1984) . Although effective in inducing regression of these lesions, termination of retinoid treatment results in their reappearance.
Here we have described an assay system which can be used for detecting compounds with anti-papillomavirus activity. Using a human t-PA gene, a simple screen has been developed which has been used to detect and evaluate interferon, and retinoic acid, producing a good correlation with results observed in the clinical treatment of HPV disease. Given the clear reduction in the levels of t-PA following treatment with either interferon or retinoic acid, this would suggest that the antiviral effect of these agents is via some mechanism of suppression of gene expression, rather than inhibition of viral DNA synthesis. While the precise mode of action of these agents in this system remains to be established, the reasons for their clinical benefit against HPV associated lesions also remains poorly understood.
Materials and Experimental procedures
Culture ot cells Mouse C127 and 310 cells, the BPV-1 transformed cell line derived from them, were grown in Dulbecco's modified Eagle's medium (Gibco, Grand Island, NY, USA)supplemented with 10% foetal calf serum.
The construction of 310 cell lines has been described previously (Browne et aI., 1988) . The t-PA expression cassette in plasmid pTR310 is under the control ofthe mouse metallothionein promoter (Fig. 6) .The particular 310 cell line used in this study was chosen on the basis of the low level oft-PA expressed, and, hence the presumed minimal effect on the host cell.
Anti-papillamavirus assay 500 fLl aliquots of appropriately diluted test compounds were added to wells of Nunc 24 well multidishes (well diameter = 1.5 em), and seeded with 1.25 x 10 4310 cells, in 500 fLl of growth medium. The assay plates were then incubated for 4 days at 37"C in a humidified atmosphere with 5% CO 2 , After this time, the cell monolayers were washed with 1 ml welr' of serum-free medium to remove serum t-PA inhibitors, and incubated overnight at 37"C in 250fLi well-1 serum-free medium. A 20fLi sample from each well was then transferred onto fibrin gels and incubated at 37"C for a further 18 h. The fibrin gel and assay plates were fixed in 10% formal saline and stained with 1% bromophenol blue and 0.1% crystal violet, respectively. Antiviral activity of the test compounds was determined by t-PA based fibrinolysis of the gel, and the compound cytotoxicity was determined by the extent of cellular damage present on the assay plate (Fig. 1) .
Formation of fibrin gels. 0.3 ml thrombin (Leo Pharmaceutical products, Ballerup, Denmark)at 50 NIH U rnr' in 0.9% saline was added to 10ml human fibrinogen (Kabi Vitrum, Stockholm, Sweden) at 10mg rnr' in a solution containing 0.03M sodium barbitone, 0.13 Msodium chloride, and 0.02 M hydrochloric acid. This was rapidly mixed, poured into a 10cm square petri dish (Sterilin Ltd, Staffordshire, UK) and allowed to set (about 1 min).
Assay calibration. The fibrinolysis system can be used for quantitative evaluation, the size of the lysis zone produced being proportional to the concentration of t-PA present (Dodd et a/., 1985) .
Antiviral evaluation of interferon and retinoic acid
Untransformed C127 and transformed 310 cells were passed in the presence or absence of (1) 200U rnl" mouse (u and 13 fibroblast) interferon (Sigma, Poole, UK) or (2)2.0 I1gmr"retinoic acid (Sigma). lnterferon-containinq medium was replenished every third day. All cells were sub-cultured, at a constant split ratio, once a week for the period of the study. At each sub-culture, a number of parameters were investigated, as follows. Confluent monolayers were washed and incubated in a minimum volume of serum-free medium for 18 h. 20111 supernatant samples were transferred to fibrin gels and, after a further 18h incubation, resultant zones of fibrinolysis were measured. The cell monolayers used for this determination were then fixed in 10% formal saline, stained with 0.1% crystal violet, and examined microscopically for morphological changes. Cell counts were also performed using a haemocytometer to determine the total density of cells achieved at confluence.
Determination of viral DNA content. To analyse the effects of interferon and retinoic acid on the viral DNA, 310 cells, cultured for 10 passages in the presence or absence of test compound, were trypsinized and applied to Hybond-C extra hybridization transfer membranes (Amersham, Aylesbury, UK) in PBS at 1 x 10 6 to 3 X 10 4 cells 10111-1 spot. Direct determination of BPV-1 DNA levels within the treated and untreated cells was performed by nucleic acid spot hybridization (Gadler, 1983; Brandsma and Miller, 1980) . Briefly, total cellular DNA was denatured in situ by exposure ofthe hybridization membrane to: 0.5 MNaOH for 6 min, 0.1 M NaOH 1.5 M-1 NaCI for 10 min, 1MTris (pH 7.5) twice for 2 min each, and 0.5M Tris 1.5M-1 NaCI for 5 min. Membranes were then air dried and baked at 80°C for 2h. Probes of pTR 310 plasmid DNAwere labelled by nick translation following manufacturer's instructions (Amersham Nick Translation Kit), and hybridizations performed in 6x SSC, 1Ox Denhardt solution, 0.1% SDS and 50 I1gmr "salmon sperm DNA at 65°Cfor 18 h (Gadler, 1983) .
After high stringency washing in 0.1 x SSC, 0.1% SDS, the membranes were exposed to Kodak X-ray film with intensifier screens at -70°C, until suitable darkening of the film was obtained.
